Selle Therapeutics "Chairman Yoon Byung-hak Takes Direct Responsibility Management to Enhance Shareholder Value"

[Asia Economy Reporter Hyunseok Yoo] Cellma Therapeutics announced on the 5th that it will actively engage in responsible management activities to enhance shareholder value.

Yoon Byung-hak, chairman of Cellma Therapeutics, increased his stake by directly participating in a third-party allotment paid-in capital increase last December. Through this capital increase, Chairman Yoon invested a total of 3 billion KRW to acquire 505,050 shares. The company explained that this share acquisition is a declaration of commitment to responsible management.

The company plans to expand responsible management in earnest, starting with Chairman Yoon’s participation in the paid-in capital increase. It also stated that the development of a treatment for COVID-19 is accelerating. Cellma Therapeutics is considering additional share acquisitions centered on Chairman Yoon.

Considering the global COVID-19 pandemic situation, Cellma Therapeutics plans to proceed with approvals quickly. Pre-IND meetings have been held in each clinical trial country. All necessary documents related to the global Phase 3 clinical trial have been prepared, bringing clinical trial applications in multiple European countries within reach. The company is also achieving financial stability. It has been confirmed that more funds were raised than initially targeted, and additional capital raising is being considered to ensure smooth clinical progress.

A Cellma Therapeutics official said, "There were market concerns about our financial status, but we worked to reduce risks last year and successfully secured funding stably. This year, we will re-evaluate corporate value through COVID-19 treatments and nano-radiation technology targeting liver and breast cancer patients, and transform into a full-fledged global bio company."

This content was produced with the assistance of AI translation services.